Recent Biosimilar Commercialization Developments
LexBlog IP
SEPTEMBER 28, 2023
has announced an exclusive licensing agreement with Tonghua Dongbao Pharmaceuticals Co., to commercialize several of Abbott’s oncology, women’s health, and respiratory disease biosimilars for emerging markets in Latin America, Southeast Asia, the Middle East, and Africa. Insulin Biosimilars: Meitheal Pharmaceuticals, Inc.
Let's personalize your content